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and Michael L. Marin, MD, New York, NY
Objective: Aneurysms involving branches of the superior mesenteric and celiac arteries are uncommon and require proper
management to prevent rupture and death. This study compares surgical and endovascular treatment of these aneurysms
and analyzes outcome.
Methods: Patients at the Mount Sinai Medical Center in New York who were treated for aneurysms in the branches of the
celiac artery and superior mesenteric artery were identified through a search of the institution’s medical records and
endovascular database. Patient demographics, history, clinical presentation, aneurysm characteristics, treatments, and
follow-up outcome were retrospectively recorded. Significant differences between patients treated by surgical or
endovascular therapy were determined by using Student’s t test and  2 analysis.
Results: Between January 1, 1991, and July 1, 2005, 59 patients with 61 aneurysms were treated at a single institution.
Twenty-four patients had surgical repair, and 35 underwent endovascular treatment, which included coil embolization
and stent-graft therapy. Splenic (28) and hepatic (22) artery aneurysms predominated. Eighty-nine percent of splenic
artery aneurysms were true aneurysms and were treated by endovascular and surgical procedures in near equal numbers
(14 and 11, respectively). Pseudoaneurysms were significantly more likely to be treated by endovascular means (P< .01).
The technical success rate of endovascular treatment for aneurysms was 89%, and failures were successfully treated by
repeat coil embolization in all patients who presented for retreatment. Patients treated by endovascular techniques had a
significantly higher incidence of malignancy than patients treated with open surgical techniques (P .03). Furthermore,
patients treated by endovascular means had a shorter in-hospital length of stay (2.4 vs 6.6 days, P < .001).
Conclusion: Endovascular management of visceral aneurysms is an effective means of treating aneurysms involving
branches of the celiac and superior mesenteric arteries and is particularly useful in patients with comorbidities, including
cancer. It is associated with a decreased length of stay in the elective setting, and failure of primary treatment can often
be successfully managed percutaneously. ( J Vasc Surg 2006;44:718-24.)Visceral artery aneurysms are an uncommon entity that
most commonly affect the splenic, hepatic, and superior
mesenteric arteries.1,2 With the increasing use of imaging
studies for a variety of nonvascular abdominal disease pro-
cesses, the diagnosis of visceral artery aneurysms is increas-
ing in the asymptomatic patient population.1,3 Although
the natural history of these lesions has not been well docu-
mented, elective repair is advocated given the high morbid-
ity and mortality associated with repair after rupture.
With the advent of endovascular techniques, the treat-
ment options for visceral artery aneurysms have been
greatly expanded beyond the conventional options of exci-
sion, bypass, and simple ligation.4 Owing to the less inva-
sive nature of endovascular repair, patients with medical
comorbidities that prohibit open repair can now be consid-
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718ered for alternative methods to treat these aneurysms.
Despite the perioperative advantages of endovascular re-
pair, the unknown long-term durability of these repairs and
the occasional need for secondary interventions has led to
uncertainty of its role in the treatment of visceral artery
aneurysms.
This study reviews a single-institution’s experience with
surgical and endovascular treatment of visceral artery aneu-
rysms during a 15-year period to determine differences in
patient characteristics and clinical outcomes between the
two groups.
METHODS
The study was approved by the Institutional Review
Board of the Mount Sinai School of Medicine. Patients
who were diagnosed and treated for aneurysms involving
branches of the celiac and superior mesenteric arteries at
Mount Sinai Medical Center over the past 15 years (1991
to 2005) were identified from hospital records using Inter-
national Classification of Disease (9th revision) codes and
an endovascular database.
Surgical management consisted of aneurysm excision
with revascularization, laparoscopic clipping, and end-
organ resection. Endovascular management included coil
embolization with platinum or stainless steel coils and
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were monitored with magnetic resonance angiography
(MRA), which reduces the artifact induced by coil emboli-
zation. In the endovascular group, the first imaging study
was performed 1 month of the procedure. The current
follow-up protocol for endovascular management of vis-
ceral aneurysms includes subsequent imaging at 3-month
intervals for the first year and yearly thereafter.
Technical success for endovascular management was
determined by the lack of aneurysm filling on completion
angiography immediately after the procedure, and on
follow-up MRA. In select cases, duplex ultrasound imaging
was used to assess flow in the aneurysm.
All splenic artery aneurysms2 cm and all those found
in liver transplant recipients, or women of childbearing age,
were treated. Additionally, all hepatic, celiac trunk, superior
mesenteric artery (SMA) trunk, gastroduodenal, and pan-
creaticoduodenal aneurysms were treated in appropriate
risk patients.
Patients were considered candidates for endovascular
management if inflow and outflow vessels to and from the
aneurysm could be accessed by a catheter-based system and
if end-organ perfusion could be maintained by collateral
blood flow or stent-graft therapy. Candidacy for endovas-
cular therapy was determined by a 2-mm-cut computed
tomography (CT) scan or thin-cut magnetic resonance
imaging (MRI).
Hemodynamic instability at the time of presentation
was defined as transfusion requirements of 2 U packed
red blood cells. Endovascular management was used in
cases of hemodynamic instability if the patient had a known
visceral artery aneurysm that was documented on either CT
scan or MRI and if the aneurysm met criteria for catheter-
based treatment. Ultimately, the decision to use endovas-
cular vs surgical management of these aneurysms was left to
the discretion of the surgeon.
Charts were reviewed for age, gender, medical and
surgical history, medications, aneurysm characteristics, pre-
senting symptoms, imaging findings at diagnosis and at
each follow-up, type of procedure(s), mode of anesthesia,
transfusion requirements, complications, reinterventions,
and mortality. Patients were considered lost to follow-up if
they did not have at least one follow-up imaging study after
endovascular management, if they did not appear for a
postoperative visit, or if records documenting follow-up
were not available.
Comparisons were made between patients treated us-
ing endovascular techniques and those treated by surgery in
regards to age, gender, major medical comorbidities (cor-
onary artery disease, pulmonary disease, diabetes, end-stage
renal disease, end-stage liver disease, and cancer), previous
surgery, aneurysm characteristics, presenting symptoms,
complications, reinterventions, and mortality. Student’s
t test and 2 were used to assess statistical significance.
RESULTS
From 1991 to 2005, 59 patients with 61 aneurysms
involving branches of the celiac and superior mesentericarteries were treated by surgical or endovascular tech-
niques. The demographics and clinical data of the patients
are summarized in Table I. Endovascular techniques were
used to treat 35 patients for 36 aneurysms (Figs 1, 2,
and 3). The most common endovascular technique to
manage the aneurysms was catheter-based coil emboliza-
tion of all inflow and outflow vessels to the lesion (n 31).
In one patient with a splenic artery aneurysm and in two
patients with hepatic artery aneurysms, stent-grafts were
placed to exclude the aneurysm and preserve blood flow
through the primary artery. In one patient with a known
superior mesenteric artery pseudoaneurysm, angiography
confirmed thrombosis of the aneurysm and no further
intervention was performed.
Most of the endovascular procedures (n  34) were
performed in an angiography suite under sedation and local
anesthesia. One patient was treated in the operating room
with coil embolization during a laparotomy for evacuation
of a hematoma.
Surgical management was used to treat 24 patients with
25 aneurysms. The procedures performed for these patients
are described in Table II. Before 2000, 14 patients (58%)
were treated surgically compared with 10 (28%) who were
treated by endovascular means (P  .02). Patients who
underwent endovascular management were more likely to
have an associated malignancy than were surgically treated
patients (P  .03). The mean age, gender, and number of
patients with previous abdominal surgery did not signifi-
Table I. Demographics and clinical status of patients
who underwent either open or endovascular repair of an
aneurysm involving the celiac and superior mesenteric
arteries are shown
Demographics
Endovascular
(n  35)
Open
(n  24)
Age 56.6 51.9
Females 13 8
Comorbidities*† 10 6
Cirrhosis 2 1
CAD 2 1
ESRD 2 1
Pulmonary 5 0
Diabetes mellitus† 9 1
Malignancy 20 10
Hypertension 4 0
Pancreatitis 4 2
Other aneurysms 0 1
Pregnancy
Patients with previous abdominal
surgery 14 7
Aneurysms of celiac origin (n) 32 24
Aneurysms of SM origin (n) 4 1
CAD, Coronary artery disease; ESRD, end-stage renal disease; SMA, supe-
rior mesenteric.
*Comorbidities in bold-face were used to calculate the number of major
comorbidities per patient.
†The P values for malignancy comorbidities were not significant, except for
malignancy (P  .03).cantly differ between the two groups.
rteria
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are described in Table III. Computerized tomography
scans were available for re-review in 47 patients for the
purpose of this study. In 12 of the 14 patients who pre-
sented with rupture, an aneurysm measurement could not
be accurately determined. In the remaining patients with
complete studies, the mean aneurysm size was 3.28 1.60
cm in the endovascular group and 4.35  1.98 cm in the
surgical group (P  .08).
Pseudoaneurysms in this study were more likely to be
treated by endovascular means: 18 (86%) of 21 were treated
using endovascular techniques, whereas only three (14%)
were treated by surgery (P .01). Hepatic artery pseudoa-
neurysms were the predominant false aneurysms in both
groups (62%) and occurred as a complication of liver trans-
plantation in 4 patients, other general surgery procedures
in 4 patients, percutaneous liver interventions in 3 patients,
and trauma in 1 patient. The remaining hepatic artery
pseudoaneurysm occurred in the setting of hepatocellular
carcinoma.
The presenting symptoms of patients in both groups
Fig 1. A, Computed tomography angiography (CTA) d
of splenic artery aneurysm before stent deployment.
deployment.D, Postoperative CTA demonstrating aneur
tissue represents differences in flow dynamics between aare shown in Table IV. There were no significant differ-ences in presentation in patients who were treated by
surgery or endovascular techniques. The aneurysm was
identified as an incidental finding in 27 patients (46%). The
most common presenting symptom was rupture, which
occurred in 14 patients and was associated with hemody-
namic instability and transfusion requirements of 2 U of
packed red blood cells. Ruptured visceral artery aneurysms
treated by endovascular techniques occurred in pseudoan-
eurysms involving the hepatic (n 6), splenic (n 1), and
superior mesenteric arteries (n  3). The ruptures treated
by open surgery involved true aneurysms of the splenic
artery in three patients and the hepatic artery in one patient.
Length of stay for elective cases treated by endovascular
means averaged 2.4  1.6 days and was significantly less
than the average length of stay for elective cases treated
surgically (6.6  4.7 days, P  .001).
Follow-up information, including postprocedure im-
aging in the endovascular group and postoperative out-
patient assessment in the surgical group, was available in
29 patients (83%) and 12 patients (46%), respectively (P 
.01) The average length of follow-up was 10.2 months
nstrates a 2.6 cm splenic artery aneurysm. B, Angiogram
ngiogram of splenic artery aneurysm after stent-graft
xclusion by stent-graft (arrow). Heterogeneity of splenic
l supply and venous sinusoids.emo
C, A
ysm e(range, 1 to 65 months) in the endovascular group and
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group (P  .06).
Patients treated with surgery, when compared with
those treated by endovascular techniques, did not differ
significantly in 30-day mortality, complications, or need for
reintervention (Table V). Elective and emergent cases in
each group did not differ in morbidity or mortality. Nine
patients (25%) in the endovascular group, had complica-
tions of their procedures, which included persistent aneu-
rysm perfusion and enlargement in four, and one patient
each with brachial artery hematoma, splenic artery dissec-
tion, liver abscess, infected pseudocyst, and pancreatitis.
Seven patients required one or more reinterventions.
The mean time to reintervention in the endovascular group
was 2.1 months (range, 0.2 to 8.1 months). Three patients
underwent successful re-embolization for persistent perfu-
sion, and one patient is scheduled for reintervention. The
mean time to reperfusion was 11.7 months (range, 0.2 to
36.7 months). Other reinterventions, in one patient each,
included evacuation of a brachial artery hematoma, distal
pancreatectomy and splenectomy for splenic artery dissec-
tion, surgical débridement of an infected pseudoaneurysm,
and percutaneous drainage of an intra-abdominal infection.
Fig 2. A, Angiogram of splenic artery aneurysm before coil em-
bolization. B, Angiogram of splenic artery aneurysm after coil
embolization.One patient with advanced pancreatic cancer and pleuraleffusions underwent embolization of a hepatic artery pseu-
doaneurysm but died 2 weeks after the procedure from
multisystem organ failure. The primary success rate for
endovascular therapy was 89%.
Six (40%) of 15 patients with splenic artery aneurysms
and follow-up imaging demonstrated splenic infarctions.
One patient, as described, had splenic artery dissection with
complete thrombosis of the splenic artery and infarction of
the spleen, requiring splenectomy. In the remaining pa-
tients, the infarctions were of no major clinical significance,
other than a source of pain that was successfully controlled
by oral pain medication. Of interest, patients who pre-
sented with postprocedure splenic infarction were more
likely to have splenomegaly associated with cirrhosis (P 
.02) Three patients with infarctions had aneurysms of the
distal splenic artery, two patients had aneurysms in the
middle of the splenic artery, and the aneurysm involved
the proximal splenic artery in one patient.
Eight patients in the surgical group had complications,
of which four required reinterventions. Complications con-
sisted of graft thrombosis and ileus in 2 patients each; and
pseudoaneurysm, bile leak, intra-abdominal abscess, and
wound infection in one patient each. Reinterventions in
this group included, in one patient each, retransplantation
of the liver for bile leak, graft thrombectomy, percutaneous
drainage of an intra-abdominal infection, and coil emboli-
Fig 3. Before (A) and after (B) stent-graft deployment for a
proper hepatic artery pseudoaneurysm originating distal to the
gastroduodenal artery. The brachial artery was used for the ap-
proach.zation for a pseudoaneurysm arising from a branch of the
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mesenteric artery to the celiac artery with saphenous vein.
One patient died in the perioperative period after splenec-
tomy and distal pancreatectomy for a ruptured splenic
Table II. Surgical treatment of true and pseudo-
aneurysms of the celiac and superior mesenteric
artery aneurysms
Location Type Operation
Celiac True Resection; bypass
GDA True GDA exclusion; bypass
Hepatic True Resection; interposition graft
Hepatic Pseudo Resection; bypass
Hepatic Pseudo Exploration and direct repair of artery
Hepatic True Resection; bypass
Hepatic True Ligation; hepatectomy
Hepatic Pseudo Ligation
Hepatic True OLT
Hepatic True Resection
Hepatic True Ligation; bypass
Hepatic Pseudo Resection; bypass
PDA True Excision; primary repair
Splenic True Splenectomy, distal pancreatectomy
Splenic True Splenectomy
Splenic True Distal pancreatectomy
Splenic True Laparoscopic aneurysm clipping
Splenic True Excision
Splenic True Splenectomy
Splenic True Splenectomy
Splenic True Splenectomy; distal pancreatectomy
Splenic True Laparoscopic aneurysm clipping
Splenic True Resection; interposition graft
Splenic True Splenectomy, distal pancreatectomy
GDA, Gastroduodenal artery aneurysm; PDA, pancreaticoduodenal artery
aneurysm; OLT, orthotopic liver transplant.
Table III. Location and classification of aneurysms
treated by either endovascular or open techniques
Aneurysm*
Endovascular
(n  35)
Open
(n  24)
Splenic
True 14 11
Pseudo 3 0
Hepatic*
True 1 7
Pseudo 10 4
Celiac trunk
True 2 1
Pseudo 0 0
Gastroduodenal
True 1 1
Pseudo 1 0
Superior mesenteric artery
True 0 0
Pseudo 3 0
Pancreaticoduodenal artery
True 0 1
Pseudo 1 0
*The P values for these aneurysms were not significant except for hepatic
(P  .002).artery aneurysm.DISCUSSION
The diagnosis of aneurysms originating from branches
of the celiac and superior mesenteric artery has increased
because of the widespread use of diagnostic imaging stud-
ies. The high morbidity and mortality associated with an-
eurysm rupture was, and remains, a major impetus to study
their etiology, progression, and treatment. However, the
increased detection of incidental aneurysms, coupled with
advancements in endovascular techniques, has mandated a
more extensive review of treatment options and indica-
tions.
Management options include observation for small an-
eurysms, endovascular treatment with catheter-based em-
bolization, and in select patients, stent-graft therapy or
surgical repair.5-14 Symptomatic splenic artery aneurysms,
those that are 2 cm, and those found in women of
childbearing age or in liver transplant recipients should be
fixed because of a high association with rupture.1,2,15-17
Elective repair is associated with mortality rates 0.5%.16
All hepatic artery true aneurysms have traditionally
warranted repair because of the high association with rup-
ture and death; furthermore, patients with a nonatheroscle-
rotic etiology and those with multiple aneurysms are at
greater risk of rupture, ranging from 14% to 80% in the
literature.18 Hepatic artery pseudoaneurysms are associated
with an increased risk of rupture, with mortality rates of
20%, and should be repaired.1 Endovascular repair for
hepatic artery pseudoaneurysms has been performed safely
and is effective.19 Aneurysms involving the celiac trunk,
Table IV. Initial presentation of patients treated either
with endovascular techniques or surgery for aneurysms of
the celiac and superior mesenteric arteries*
Presentation Endovascular Open
Incidental 18 10
Symptomatic 18 14
Pain 5 7
Rupture 10 4
Gastrointestinal bleeding 1 1
Hemobilia 1 1
Infected pseudocyst 1 1
*The P values for these data are not significant.
Table V. Complications, reinterventions, and 30-day
mortality after open or endovascular repair of aneurysms
involving branches of the celiac and superior mesenteric
arteries*
Endovascular
(n  35)
Open
(n  24)
Complications 9 8
Reinterventions 7 4
Deaths 30 days 1 1
*The P values for these data are not significant.superior mesenteric artery, gastroduodenal artery, pancre-
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able rupture rate, and should be repaired if treatment can be
associated with low morbidity and mortality.12,20
Historically, small series of25 patients have predom-
inated in the literature regarding etiology and treatment of
visceral artery aneurysms. During the past 5 years, larger
series have been published that detail the experience with
surgical and endovascular management, as well as observa-
tion.3,17,18,21,22 This study adds to the current literature on
aneurysms of the celiac and superior mesenteric arteries,
not only because it describes a large series of patients but
also because all of the patients in this study received treat-
ment. Approximately equal numbers of patients have been
treated at our institution by surgical and endovascular
means during the last 15 years, which enables a comparison
between the two treatment options regarding patient selec-
tion, length of stay, morbidity, and mortality.
The initial technical success rate for the endovascular
procedures was 89%, similar to that reported by oth-
ers.4,11,19,20 Secondary interventions for persistent perfu-
sion were successfully performed in three patients, suggest-
ing that failures of primary treatment need not require
surgical management to ensure aneurysm exclusion. Persis-
tent perfusion represented the most common complication
of elective therapy, occurring in 11% of those patients. In
the literature, lack of complete aneurysm exclusion ranges
from 4% to 43%, and, along with infarction, is one of the
major limitations of this procedure.4,20
The length of stay for elective cases was significantly less
for the endovascular group than the open group in the
present study. Currently, coil embolization of a splenic
artery aneurysm is performed as an ambulatory procedure,
and in most patients, it represents our initial treatment of
choice for this clinical entity.
Complication rates in both groups did not differ for
either elective or emergent cases, and are within the re-
ported range in the literature.1,18 Similarly, the reinterven-
tion rate was not significantly different between the endo-
vascular and surgical groups, and included procedures
related to persistent perfusion, graft thrombosis, distal isch-
emia, and infection. The number of patients with follow-up
information was significantly less in the surgical group,
however, suggesting that differences in the complication
and reintervention rates might be underestimated. Thus, it
is not possible from the data in the present study to con-
clude that endovascular treatment is superior to surgical
management in regards to morbidity and need for second-
ary procedures.
Forty percent of patients who underwent endovascular
treatment of splenic artery aneurysms had radiographic
evidence of splenic infarctions. To date, however, none of
these patients have presented with splenic abscess, or other
sequelae, and most were successfully managed with pain
control. Although other series have documented splenic
infarctions after embolization, there is a paucity of informa-
tion concerning its significance.23,24 Other series have sug-
gested that infarction appears to be associated with aneu-
rysms located distally on the splenic artery.3 In our series,splenic artery infarction was significantly associated with
cirrhosis.
Patients with rupture and hemodynamic instability
were successfully treated by endovascular means. The data
suggest that hemodynamic instability does not preclude
successful endovascular management, which may be the
treatment of choice in patients with associated comorbidi-
ties. Although all of the ruptures managed by open surgery
were true aneurysms, those that were treated by endovas-
cular means were pseudoaneurysms. Pseudoaneurysms, as a
group, were dominated by hepatic pseudoaneurysms and
were significantly more likely to be treated using endovas-
cular techniques. This likely reflected an attempt to avoid
difficult surgery in patients with multiple comorbidities,
including cirrhosis and cancer, and has been reported as an
effective strategy in other series.5,10
CONCLUSION
In conclusion, endovascular management is an effective
means of treating aneurysms involving the celiac and supe-
rior mesenteric arteries and their branches. It is associated
with a decreased length of stay in the elective setting, and
failure of primary treatment can be successfully managed
with a repeat percutaneous procedure. Endovascular repair
is particularly useful in patients with multiple comorbidi-
ties, particularly malignancy, and can be used in cases of
hemodynamic instability. Further long-term data will help
elucidate whether morbidity and durability truly differs
between endovascular and surgical treatments.
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